Representative before the EPO

Company dna voellmy patent attorney
no operation time available
1 office
active in Legal Services

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Company dna hsf pharmaceuticals sa
no operation time available
1 office
active in Legal Services

We have observed 29 EP applications Lukas Völlmy has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after June 28, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12704407

CEFUROXIME SAFETY DELIVERY SYSTEM

IPC classification:
A61M 5/24, A61M 5/19, A61J 1/20, A61M 5/315, A61M 5/178, A61K 9/00
Agent:
Lukas Völlmy, VOELLMY (Patent Attorney)
Status:
EXAMINATION IN PROGRESS
EP12710051

THERMO-RESPONSIVE HYDROGEL COMPOSITIONS

IPC classification:
A61K 47/48, A61K 47/32
Agent:
Lukas Völlmy, VOELLMY (Patent Attorney)
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12729116

NKp46-MEDIATED NK CELL TUNING

IPC classification:
A61K 39/00, A61K 38/17
Applicant:
Université de la Méditerranée - Aix-Marseille II
Applicant:
Innate Pharma SA
Applicant:
Centre National de la Recherche Scientifique (CNRS)
Applicant:
Institut National de la Santé et de la Recherche Médicale (INSERM)
Agent:
Lukas Völlmy, Innate Pharma SA
Agent:
Matthieu Collin, Inserm Transfert
Status:
GRANT OF PATENT INTENDED
EP12812651

ENZYMATIC CONJUGATION OF ANTIBODIES

IPC classification:
A61K 47/48, A61P 35/00
Applicant:
Innate Pharma SA
Applicant:
Paul Scherrer Institut
Agent:
Lukas Völlmy, Innate Pharma SA
Agent:
Valérie Gallois, Cabinet Becker & Associés
Status:
GRANT OF PATENT INTENDED
EP13704064

MICA BINDING AGENTS

IPC classification:
A61K 39/395, C07K 16/28, A61P 35/00
Applicant:
Innate Pharma SA
Agent:
Lukas Völlmy, Innate Pharma SA
Agent:
Valérie Gallois, Cabinet Becker & Associés
Status:
EXAMINATION IN PROGRESS
EP14191805

Transglutaminase mediated conjugation of peptides

IPC classification:
A61K 47/48, A61K 38/27, C12P 21/00, C07K 14/61
Applicant:
Novo Nordisk Health Care AG
Agent:
Lukas Völlmy, Innate Pharma SA
Agent:
Valérie Gallois, Cabinet Becker & Associés
Status:
PATENT GRANTED
EP13765703

KIR3DL2 BINDING AGENTS

IPC classification:
G01N 33/569, C07K 16/28
Applicant:
Innate Pharma SA
Agent:
Valérie Gallois, Cabinet Becker & Associés
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
EXAMINATION IN PROGRESS
EP13765702

KIR3DL2 BINDING AGENTS

IPC classification:
G01N 33/569, C07K 16/28
Applicant:
Innate Pharma SA
Agent:
Valérie Gallois, Cabinet Becker & Associés
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
EXAMINATION IN PROGRESS
EP13791777

RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION

IPC classification:
A61K 47/48
Applicant:
Innate Pharma SA
Applicant:
Paul Scherrer Institut
Agent:
Valérie Gallois, Cabinet Becker & Associés
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
EXAMINATION IN PROGRESS
EP14704576

TREATMENT OF PERIPHERAL T CELL LYMPHOMA

IPC classification:
A61P 35/00, A61K 39/395, C07K 16/30, C07K 16/28
Applicant:
Innate Pharma SA
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
The patent has been granted
EP14706017

A COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/30, C07K 16/28
Applicant:
Innate Pharma SA
Agent:
Valérie Gallois, Cabinet Becker & Associés
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
EXAMINATION IN PROGRESS
EP14723452

METHODS FOR RESTORING CORTICOSTEROID SENSITIVITY

IPC classification:
C07K 16/28, A61P 37/00, A61P 19/02, A61P 11/00, A61K 39/395, A61K 39/00
Applicant:
Innate Pharma SA
Agent:
Valérie Gallois, Cabinet Becker & Associés
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
EXAMINATION IN PROGRESS
EP14731962

ENZYMATIC CONJUGATION OF POLYPEPTIDES

IPC classification:
A61K 47/48
Applicant:
Innate Pharma SA
Agent:
Valérie Gallois, Cabinet Becker & Associés
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
GRANT OF PATENT INTENDED
EP14734427

ENZYMATIC CONJUGATION OF POLYPEPTIDES

IPC classification:
A61K 47/48
Applicant:
Paul Scherrer Institut
Applicant:
Innate Pharma SA
Agent:
Valérie Gallois, Cabinet Becker & Associés
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
GRANT OF PATENT INTENDED
EP15709212

HUMANIZED ANTIBODIES WITH INCREASED STABILITY

IPC classification:
A61K 39/00, A61K 39/395, A61P 35/00, C07K 16/30, C07K 16/28
Applicant:
Innate Pharma SA
Agent:
Valérie Gallois, Cabinet Becker & Associés
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
EXAMINATION REQUESTED
EP15731564

MULTISPECIFIC NKp46 BINDING PROTEINS

IPC classification:
C07K 16/46, C07K 16/28
Applicant:
Innate Pharma SA
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
EXAMINATION REQUESTED
EP15762508

NOVEL IMMUNIZATION AGENTS AND METHODS OF USE

IPC classification:
A61K 39/00, A61K 39/12
Agent:
Lukas Völlmy, HSF Pharmaceuticals SA
Status:
EXAMINATION REQUESTED
EP15762562

CROSS REACTIVE SIGLEC ANTIBODIES

IPC classification:
A61P 35/00, C07K 16/28
Applicant:
Innate Pharma SA
Agent:
Valérie Gallois, Cabinet Becker & Associés
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
Request for examination was made
EP15784928

MANAGING NETWORK FORWARDING CONFIGURATIONS USING ALGORITHMIC POLICIES

IPC classification:
H04L 12/24
Agent:
Lukas Völlmy, HSF Pharmaceuticals SA
Status:
Request for examination was made
EP15763016

TREATMENT REGIMENS USING ANTI-NKG2A ANTIBODIES

IPC classification:
A61K 39/00, A61P 29/00, A61P 35/00, C07K 16/28, A61K 39/395
Applicant:
Innate Pharma SA
Agent:
Valérie Gallois, Cabinet Becker & Associés
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
Request for examination was made
EP15766120

NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES

IPC classification:
A61K 39/00, A61P 35/00, C07K 16/28, A61K 39/395
Applicant:
Innate Pharma SA
Agent:
Valérie Gallois, Cabinet Becker & Associés
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
Request for examination was made
EP15778310

CD73 BLOCKADE

IPC classification:
C07K 16/30, C07K 16/40, C07K 16/28
Applicant:
Innate Pharma SA
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
Request for examination was made
EP15784685

TREATMENT OF CANCERS USING ANTI-NKG2A AGENTS

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28
Applicant:
Innate Pharma SA
Agent:
Valérie Gallois, Cabinet Becker & Associés
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
Request for examination was made
EP15822939

ENZYMATIC CONJUGATION OF POLYPEPTIDES

IPC classification:
A61K 47/50
Applicant:
Innate Pharma SA
Applicant:
Paul Scherrer Institut
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
Request for examination was made
EP16700287

MONOMERIC FC DOMAINS

IPC classification:
C07K 16/46, C07K 16/28
Applicant:
Innate Pharma SA
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
Request for examination was made
EP17177583

TREATMENT OF PERIPHERAL T CELL LYMPHOMA

IPC classification:
A61P 35/00, A61K 39/395, G01N 33/574, C07K 16/30, C07K 16/28
Applicant:
Innate Pharma SA
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
The application has been published
EP16709299

CD73 BLOCKADE

IPC classification:
C07K 16/30, C07K 16/40, C07K 16/28
Applicant:
Innate Pharma SA
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
Request for examination was made
EP16734592

MULTISPECIFIC NK ENGAGER PROTEINS

IPC classification:
C07K 16/46, C07K 16/28
Applicant:
Innate Pharma SA
Agent:
Lukas Völlmy, Innate Pharma SA
Agent:
Valérie Gallois, Cabinet Becker & Associés
Status:
Request for examination was made
EP16736054

METHODS FOR DETECTING TISSUE INFILTRATING NK CELLS

IPC classification:
G01N 33/574, C12N 5/07, G01N 33/566
Applicant:
Innate Pharma SA
Agent:
Lukas Völlmy, Innate Pharma SA
Status:
Request for examination was made

Please Sign in to use this feature